Ep. 330 - China's Innovation Moment

October 31, 2025·43 min·3 clips

Duality Biologics CEO John Zhu explains China speed in concrete terms: IND to first patient in 45 days versus the 3-4 months US companies call normal, and end-of-dose-escalation meeting in 20 months versus the 3-4 years Western companies expect.

Shanghai is the setting. The conversation comes out of BioCentury's 12th China Healthcare Summit, where the panel looks at how quickly Asia biotech is changing and what still has to prove out. The discussion stays commercial. China innovation is not treated like a catchphrase. The speakers keep coming back to balance sheets, commercialization muscle, and the cost of going global. InnoVent is the first test case. Its Takeda deal gets attention partly because it did not default to a big US pharma partner. Scale is still the choke point. One guest says only three or four China biotechs currently have the resources to act from a truly global position. Legend sets the precedent. Carvecchi is described as the first China-originated therapy to fundamentally change global standard of care, which makes it more than a tidy deal story. That is a hard bar to clear. The panel keeps asking whether China speed, efficient capital, and local commercialization can turn into therapies that matter everywhere. Akiso comes into that comparison. Ivanissimab is held up as another hoped-for candidate with broader global reach, with lung cancer giving it a larger addressable market than multiple myeloma. The tone stays skeptical. A global outlook is not something a biotech can simply claim. Most companies still need capital, and many give up more economics later. Deal structure matters here. Partnership choices, commercialization records, and company size help separate durable global contenders from thinner stories. The summit setting widens the frame, with Charles Rivers, Duality Biologics, Akiso, BioCentury's editorial team, and the Bay Helix network circling the same question about Asia's next phase. Seoul is the next marker, with the 5th East-West Summit in Seoul, Korea pointing to an opportunity set beyond one market or one conference cycle.

As heard by us

A Shanghai panel that links China biotech financing, partnering, and global ambition without hand-waving.

BioCentury This Week uses the Shanghai summit to frame a familiar but useful gap: China biotech can be strong at home while still working to widen its global reach.

Read the full review in PlayNext →

Why you'd press play

Need the China biotech read behind the Hong Kong IPO wave and the summit chatter?

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from BioCentury This Week